Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paradigm5: N9-GP in previously treated children with haemophilia B
jRCT2080221833Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2012
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 3, open-label, single-arm trial of nonacog beta pegol in hemophilia B (HB), sponsored by Novo Nordisk. Primary endpoints: Safety of N9-GP prophylaxis, Efficacy of N9-GP prophylaxis and 1 more. Started Jun 2012; status: completed.
02
Drugs
nonacog beta pegol
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on jRCT2080221833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221833.